The company has filed an IND application (Investigational New Drug Application) and hopes to initiate a Phase 1 trial before the end of the year, pending FDA clearance.
The study will evaluate the safety, tolerability and pharmacokinetics of SAN2465 in healthy volunteers. It will also include validated cognitive tests and established pharmacodynamic measures, facilitating the definition of the dose range for future clinical studies in patients.
BREAKING